GPN Vaccines to Highlight Serotype Independent Bacterial Vaccine Platform at Leading International Vaccines Congresses
Presentations will feature Gamma-PN clinical progress and early Gamma-SU findings supporting a broader approach to human and animal health NEW YORK, Sept. 28, 2026 /PRNewswire/ -- GPN Vaccines, Inc., a clinical-stage biotechnology company developing a new generation of broadly protective...
Covered in this story
What has happened since
- Global Payments is up 0.2% since this was published, 22 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Global Payments
- Cantor Fitzgerald: $86.1 → $91 by Aug 2027 · Neutral via Investing.com
- Morgan Stanley: $82.4 → $100 by Jul 2027 · Overweight via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $GPN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Global Payments →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.